Big Sky Biomedical Appoints Dr. Ryan Egeland as Managing Director

March 7, 2022—Big Sky Biomedical, a medical device and health technology incubator, announced that it has appointed Founding Partner Ryan Egeland, MD, as Managing Director. Big Sky Biomedical, which was founded by a group of medical device serial entrepreneurs with extensive expertise in the cardiovascular space, is a specialized incubator focused on rapid, capital-efficient therapy development.

According to the company, Dr. Egeland previously served as the Head of Strategic Ventures and Chief Medical Officer for Cardiovascular Systems, Inc. Before that he led teams in Business Development & Licensing, Medical & Scientific Affairs, and Product Marketing at Medtronic, Covidien, and ev3.

Dr. Egeland trained as a plastic and reconstructive surgeon at Northwestern Memorial Hospital in Chicago, Illinois, and has practiced in both large academic hospital and office-based lab settings. He received his medical degree from Harvard Medical School in Boston, Massachusetts, and completed his PhD and MBA as a Rhodes Scholar at the University of Oxford in the United Kingdom.

“Big Sky Biomedical was founded to enhance early-stage innovation and development in some of the fastest growing segments of health care, including neurovascular, structural heart, and regenerative medicine,” commented Dr. Egeland in the company’s press release. “I’m extremely excited to apply my scientific, medical, and commercial experience to our portfolio companies in a much broader and deeper capacity. Alongside our exceptional teams of engineers, scientists, operators, and physician partners, I look forward to addressing significant underserved patient populations and large unmet clinical needs through compelling and differentiated technologies.”

“We are exceedingly pleased to welcome Ryan in a managing role at Big Sky Biomedical,” stated JC Sun, Founding Partner of the incubator. “Ryan brings extensive, cross-functional expertise to our nimble, capital-efficient companies. With his guidance and operational involvement, not only am I very confident in our ability to execute in the near term but am extremely bullish about Big Sky’s potential to streamline zero to one value creation, setting a new standard for accelerating next-level medical device design and development.”